The effect of intravenous glucocorticoids on the tearfilm in eyes with thyroid-associated ophthalmopathy - Tearfilm in eyes with TAO

Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie0 个研究点目标入组 24 人开始时间: 2012年4月30日最近更新: 2018年8月20日

适应症

试验速览

暂无简介。

•- Men and women aged over 18 years
•- Active thyroid associated ophthalmopathy with clinical activity score (CAS) of each eye more than 3 or recently experienced worsening of proptosis, lid retraction, or ocular motility disturbance.
•- Normal ophthalmic findings except symptoms associated with TAO
•- Scheduled for treatment with systemic glucocorticoids according to the kahaly-scheme
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 12
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 12

•- Chronic inactive TAO
•- Previous treatment with oral or intravenous glucocorticoids 3 months preceeding the study
•- Participation in a clinical trial in the 3 weeks before the screening visit
•- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
•- Presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator
•- Wearing of contact lenses
•- Intake of dietary supplements in the 3 months preceding the study
•- Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except topical lubricants
•- Ocular infection
•- Ocular surgery in the 3 months preceding the study
•- Sjögren’s syndrome
•- Stevens-Johnson syndrome
•- Pregnancy, planned pregnancy or lactating

发起方

Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie